Genentech rebuts Roche pessimism

Genentech rebuts Roche pessimism

Roche's criticism Genentech response
Future pricing - increases assumed Genentech assumed portfolio-weighted average price increases of about 3.6% in 2009, trending down to about optimistic 2.3% by 2015 due to factors that include the company's expectation of a potentially more challenging competitive and reimbursement environment. Moreover, according to the biotech: •Portfolio-weighted average

Read the full 592 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE